Effect of Lumican on the Migration of Human Mesenchymal Stem Cells and Endothelial Progenitor Cells: Involvement of Matrix Metalloproteinase-14

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Malinowski, Mariusz ^a,b   Pietraszek, Katarzyna ^a   Perreau, Corinne ^a   Boguslawski, Mateusz ^a   Decot, Véronique ^c   Stoltz, Jean François ^c   Vallar, Laurent ^d   Niewiarowska, Jolanta ^e   Cierniewski, Czeslaw ^b   Maquart, François Xavier ^a,f   Wegrowski, Yanusz ^a   Brézillon, Stéphane ^a   Karamanos, Nikos K ^g  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b INSTITUTE OF MEDICAL BIOLOGY   (Poland)

^c CHU NANCY BRABOIS   (France)

^d LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f REIMS UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

LUMICAN; MATRIX METALLOPROTEINASE 14;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINASE INHIBITION;

APOPTOSIS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHONDROITIN SULFATE PROTEOGLYCANS; DOWN-REGULATION; ENDOTHELIAL CELLS; HUMANS; KERATAN SULFATE; MATRIX METALLOPROTEINASE 14; MESENCHYMAL STROMAL CELLS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 84870858903     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050709     Document Type: Article

References (51)

1. Semon JA, Nagy LH, Llamas CB, Tucker HA, Lee RH, et al. (2010) Integrin expression and integrin-mediated adhesion in vitro of human multipotent stromal cells (MSCs) to endothelial cells from various blood vessels. Cell Tissue Res 341(1): 147-158.
2. Lu C, Li XY, Hu Y, Rowe RG, Weiss SJ, (2010) MT1-MMP controls human mesenchymal stem cell trafficking and differentiation. Blood 115(2): 221-229.
3. Cheng XW, Kuzuya M, Nakamura K, Maeda K, Tsuzuki M, et al. (2007) Mechanisms underlying the impairment of ischemia-induced neovascularization in matrix metalloproteinase 2-deficient mice. Circ Res 100(6): 904-913.
4. Huang PH, Chen YH, Wang CH, Chen JS, Tsai HY, et al. (2009) Matrix metalloproteinase-9 is essential for ischemia-induced neovascularization by modulating bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol 29(8): 1179-1184.
5. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, et al. (2004) Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22(3): 377-384.
6. Moby V, Labrude P, Kadi A, Bordenave L, Stoltz JF, et al. (2011) Polyelectrolyte multilayer film and human mesenchymal stem cells: an attractive alternative in vascular engineering applications. J Biomed Mater Res 96(2): 313-319.
7. Gao D, Nolan D, McDonnell K, Vahdat L, Benezra R, et al. (2009) Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 1796(1): 33-40.
8. Rafii S, Meeus S, Dias S, Hattori K, Heissig B, et al. (2002) Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol 13(1): 61-67.
9. Gruber R, Kandler B, Holzmann P, Vögele-Kadletz M, Losert U, et al. (2005) Bone marrow stromal cells can provide a local environment that favors migration and formation of tubular structures of endothelial cells. Tissue Eng 11(5-6): 896-903.
10. Chen XD, (2010) Extracellular matrix provides an optimal niche for the maintenance and propagation of mesenchymal stem cells. Birth Defects Res C Embryo Today 90(1): 45-54.
11. Bi Y, Stuelten CH, Kilts T, Wadhwa S, Iozzo RV, et al. (2005) Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. J Biol Chem 280(34): 30481-30489.
12. Kao WW, Funderburgh JL, Xia Y, Liu CY, Conrad GW, (2006) Focus on molecules: lumican. Exp Eye Res 82(1): 3-4.
13. Grover J, Chen XN, Korenberg JR, Roughley PJ, (1995) The human lumican gene. Organization, chromosomal location, and expression in articular cartilage. J Biol Chem 270(37): 21942-21949.
14. Corpuz LM, Funderburgh JL, Funderburgh ML, Bottomley GS, Prakash S, et al. (1996) Molecular cloning and tissue distribution of keratocan. Bovine corneal keratan sulfate proteoglycan 37A. J Biol Chem 271(16): 9759-9763.
15. Dolhnikoff M, Morin J, Roughley PJ, Ludwig MS, (1998) Expression of lumican in human lungs. Am J Respir Cell Mol Biol 19(4): 582-587.
16. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, et al. (1998) Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J Cell Biol 141(5): 1277-1286.
17. Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, et al. (2003) Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin. Cancer Res 9(1): 207-214.
18. Vuillermoz B, Khoruzhenko A, D'Onofrio MF, Ramont L, Venteo L, et al. (2004) The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res 296(2): 294-306.
19. Brézillon S, Venteo L, Ramont L, D'Onofrio MF, Perreau C, et al. (2007) Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma. Clin Exp Dermatol 32(4): 405-416.
20. Brézillon S, Radwanska A, Zeltz C, Malkowski A, Ploton D, et al. (2009) Lumican core protein inhibits melanoma cell migration via alterations of focal adhesion complexes. Cancer Lett 283(1): 92-100.
21. D'Onofrio MF, Brézillon S, Baranek T, Perreau C, Roughley PJ, et al. (2008) Identification of beta1 integrin as mediator of melanoma cell adhesion to lumican. Biochem Biophys Res Commun 365(2): 266-272.
22. Zeltz C, Brézillon S, Käpylä J, Eble JA, Bobichon H, et al. (2010) Lumican inhibits cell migration through alpha2beta1 integrin. Exp Cell Res 316(17): 2922-2931.
23. Albig AR, Roy TG, Becenti DJ, Schiemann WP, (2007) Transcriptome analysis of endothelial cell gene expression induced by growth on matrigel matrices: identification and characterization of MAGP-2 and lumican as novel regulators of angiogenesis. Angiogenesis 10(3): 197-216.
24. Brézillon S, Zeltz C, Schneider L, Terryn C, Vuillermoz B, et al. (2009) Lumican inhibits B16F1 melanoma cell lung metastasis. J Physiol Pharmacol 60Suppl 4: 15-22.
25. Radwanska A, Baczynska D, Nowak D, Brézillon S, Popow A, et al. (2008) Lumican affects actin cytoskeletal organization in human melanoma A375 cells. Life Sci 83(19-20): 651-660.
26. Williams KE, Fulford LA, Albig AR, (2010) Lumican reduces tumor growth via induction of fas-mediated endothelial cell apoptosis. Cancer Microenviron 4(1): 115-126.
27. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, et al. (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7(11): 1194-1201.
28. Brew K, Nagase H, (2010) The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803(1): 55-71.
29. Davis GE, Saunders WB, (2006) Molecular balance of capillary tube formation versus regression in wound repair: role of matrix metalloproteinases and their inhibitors. J Investig Dermatol Symp Proc 11(1): 44-56.
30. Niewiarowska J, Brézillon S, Sacewicz-Hofman I, Bednarek R, Maquart FX, et al. (2011) Lumican inhibits angiogenesis by interfering with alpha2beta1 receptor activity and downregulating MMP-14 expression. Thromb Res 128(5): 452-457.
31. Lozito TP, Tuan RS, (2011) Mesenchymal stem cells inhibit both endogenous and exogenous MMPs via secreted TIMPs. J Cell Physiol 226(2): 385-396.
32. Ries C, Egea V, Karow M, Kolb H, Jochum M, et al. (2007) MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 109(9): 4055-4063.
33. Berthelemy N, Kerdjoudj H, Schaaf P, Prin-Mathieu C, Lacolley P, et al. (2009) O2 level controls hematopoietic circulating progenitor cells differentiation into endothelial or smooth muscle cells. PLoS One 4(5): e5514.
34. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, et al. (2005) Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 33(11): 1402-1416.
35. Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, et al. (2006) Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24(5): 1254-1264.
36. Ling L, Nurcombe V, Cool SM, (2009) Wnt signaling controls the fate of mesenchymal stem cells. Gene 433(1-2): 1-7.
37. Chen XD, Dusevich V, Feng JQ, Manolagas SC, Jilka RL, (2007) Extracellular matrix made by bone marrow cells facilitates expansion of marrow-derived mesenchymal progenitor cells and prevents their differentiation into osteoblasts. J Bone Miner Res 22(12): 1943-1956.
38. Caiado F, Real C, Carvalho T, Dias S, (2008) Notch pathway modulation on bone marrow-derived vascular precursor cells regulates their angiogenic and wound healing potential. PLoS One 3(11): e3752.
39. Lozito TP, Kuo CK, Taboas JM, Tuan RS, (2009) Human mesenchymal stem cells express vascular cell phenotypes upon interaction with endothelial cell matrix. J Cell Biochem 107(4): 714-722.
40. Vij N, Roberts L, Joyce S, Chakravarti S, (2005) Lumican regulates corneal inflammatory responses by modulating Fas-Fas ligand signaling. Invest Ophthalmol Vis Sci 46(1): 88-95.
41. Omoteyama K, Inoue S, (2007) The variation in Fas localization and the changes in Fas expression level upon stimulation with growth factors. Biochem Biophys Res Commun 353(1): 159-163.
42. Lee S, Bowrin K, Hamad AR, Chakravarti S, (2009) Extracellular matrix lumican deposited on the surface of neutrophils promotes migration by binding to β2 integrin. J Biol Chem 284(35): 23662-23669.
43. Jazayeri M, Allameh A, Soleimani M, Jazayeri SH, Piryaei A, et al. (2008) Molecular and ultrastructural characterization of endothelial cells differentiated from human bone marrow mesenchymal stem cells. Cell Biol Int 32(10): 1183-1192.
44. Aguirre A, Planell JA, Engel E, (2010) Dynamics of bone marrow-derived endothelial progenitor cell/mesenchymal stem cell interaction in co-culture and its implications in angiogenesis. Biochem Biophys Res Commun 400(2): 284-291.
45. Liu Y, Cooper PR, Barralet JE, Shelton RM, (2007) Influence of calcium phosphate crystal assemblies on the proliferation and osteogenic gene expression of rat bone marrow stromal cells. Biomaterials 28(7): 1393-1403.
46. Geng Y, McQuillan D, Roughley PJ, (2006) SLRP interaction can protect collagen fibrils from cleavage by collagenases. Matrix Biol 25(8): 484-491.
47. Ho IA, Chan KY, Ng WH, Guo CM, Hui KM, et al. (2009) Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells 27(6): 1366-1375.
48. Lecomte J, Louis K, Detry B, Blacher S, Lambert V, et al. (2011) Bone marrow-derived mesenchymal cells and MMP13 contribute to experimental choroidal neovascularization. Cell Mol Life Sci 68(4): 677-686.
49. Thevenard J, Ramont L, Devy J, Brassart B, Dupont-Deshorgue A, et al. (2010) The YSNSG cyclopeptide derived from tumstatin inhibits tumor angiogenesis by down-regulating endothelial cell migration. Int J Cancer 126(5): 1055-1066.
50. Li Y, Aoki T, Mori Y, Ahmad M, Miyamori H, et al. (2004) Cleavage of lumican by membrane-type matrix metalloproteinase-1 abrogates this proteoglycan-mediated suppression of tumor cell colony formation in soft agar. Cancer Res 64(19): 7058-7064.
51. Mimura T, Chang JH, Kim TI, Onguchi T, Kojima T, et al. (2011) MT1-MMP cleavage of the antiangiogenic proteoglycan decorin: role in corneal angiogenesis. Cornea 30Suppl 1: S45-S49.